Cargando…

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

SIMPLE SUMMARY: Although the role of HER2 in prostate cancer remains controversial, HER2 can be overexpressed during prostate cancer progression. In this study, we prospectively isolated circulating tumor cells (CTCs) from 41 men with metastatic castration-resistant prostate cancer (mCRPC). Then, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maillet, Denis, Allioli, Nathalie, Péron, Julien, Plesa, Adriana, Decaussin-Petrucci, Myriam, Tartas, Sophie, Sajous, Christophe, Ruffion, Alain, Crouzet, Sébastien, Freyer, Gilles, Vlaeminck-Guillem, Virginie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656805/ https://www.ncbi.nlm.nih.gov/pubmed/34885125 http://dx.doi.org/10.3390/cancers13236014

Ejemplares similares

Differentially Expressed Androgen-Regulated Genes in Androgen-Sensitive Tissues Reveal Potential Biomarkers of Early Prostate Cancer
por: Altintas, Dogus Murat, et al.
Publicado: (2013)

PCA3 and PCA3-Based Nomograms Improve Diagnostic Accuracy in Patients Undergoing First Prostate Biopsy
por: Ruffion, Alain, et al.
Publicado: (2013)

Comparative Evaluation of Urinary PCA3 and TMPRSS2: ERG Scores and Serum PHI in Predicting Prostate Cancer Aggressiveness
por: Tallon, Lucile, et al.
Publicado: (2014)

Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer
por: Vlaeminck-Guillem, Virginie
Publicado: (2020)

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
por: Pérot, Philippe, et al.
Publicado: (2013)

Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine
por: Descotes, Françoise, et al.
Publicado: (2017)

Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives
por: Varnier, Romain, et al.
Publicado: (2021)

Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
por: Reverdy, Thibaut, et al.
Publicado: (2020)

COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study
por: Péron, Julien, et al.
Publicado: (2021)

When Prostate Cancer Circulates in the Bloodstream
por: Vlaeminck-Guillem, Virginie
Publicado: (2015)

Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management
por: Vlaeminck-Guillem, Virginie
Publicado: (2018)

Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)
por: Colomban, Olivier, et al.
Publicado: (2020)

Embryonated Chicken Tumor Xenografts Derived from Circulating Tumor Cells as a Relevant Model to Study Metastatic Dissemination: A Proof of Concept
por: Rousset, Xavier, et al.
Publicado: (2022)

Src: Marker or Actor in Prostate Cancer Aggressiveness
por: Vlaeminck-Guillem, Virginie, et al.
Publicado: (2014)

Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers
por: Rouvière, Olivier, et al.
Publicado: (2017)

Characterization of high-grade prostate cancer at multiparametric MRI: assessment of PI-RADS version 2.1 and version 2 descriptors across 21 readers with varying experience (MULTI study)
por: Di Franco, Florian, et al.
Publicado: (2023)

Case Report: Comorbid Hyper-IgD Syndrome and Hidradenitis Suppurativa – A New Syndromic Form of HS? A Report of Two Cases
por: Guillem, Philippe, et al.
Publicado: (2022)

Detection of ISUP ≥2 prostate cancers using multiparametric MRI: prospective multicentre assessment of the non-inferiority of an artificial intelligence system as compared to the PI-RADS V.2.1 score (CHANGE study)
por: Rouvière, Olivier, et al.
Publicado: (2022)

HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
por: Essadi, Ismail, et al.
Publicado: (2023)

Prevalence of differentiated thyroid cancer in 810 cases of surgically treated goiter in Yemen
por: Al-Jaradi, Mansour, et al.
Publicado: (2005)

MiR-7-5p inhibits thyroid cell proliferation by targeting the EGFR/MAPK and IRS2/PI3K signaling pathways
por: Augenlicht, Alice, et al.
Publicado: (2021)

Primary thyroid rhabdomyosarcoma in an adult: A challenging case with histomolecular diagnosis and literature review
por: Alsugair, Ziyad, et al.
Publicado: (2023)

Methods and Designs of Modern Breast Cancer Confirmatory Trials
por: Péron, Julien, et al.
Publicado: (2021)

MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin
por: Luo, Yakun, et al.
Publicado: (2021)

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
por: Vano, Yann-Alexandre, et al.
Publicado: (2021)

New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer
por: Saiselet, Manuel, et al.
Publicado: (2015)

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
por: Hamizi, Salima, et al.
Publicado: (2013)

The fate of the duplicated androgen receptor in fishes: a late neofunctionalization event?
por: Douard, Véronique, et al.
Publicado: (2008)

The scaffold protein menin is essential for activating the MYC locus and MYC‐mediated androgen receptor transcription in androgen receptor‐dependent prostate cancer cells
por: Luo, Yakun, et al.
Publicado: (2021)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
por: Collet, Laetitia, et al.
Publicado: (2022)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase
por: Jathal, Maitreyee K., et al.
Publicado: (2019)

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)

PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy
por: Nechifor-Boilă, Ioan Alin, et al.
Publicado: (2021)

Thyroid liposarcoma: a case report
por: Gerard, Maxime, et al.
Publicado: (2022)

Abstract of Letter from Dr. Sajous to Dr. Gaston
por: Sajous, Chas. Eden
Publicado: (1897)

The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity
por: Pellecchia, Simona, et al.
Publicado: (2020)

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis
por: Chen, Shinan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_spisvtva7qkhv6j7du3lcbod6j